Pioglitazone/metformin

Anji Pharma Launches Phase 3 Trial for ANJ900 to Treat Type 2 Diabetes Patients with Kidney Disease

Retrieved on: 
Thursday, June 10, 2021
Diabetes, Other Health, Pharmaceutical, Women, Seniors, Hospitals, Fitness & Nutrition, MEN, Clinical trials, Science, Biotechnology, Consumer, Other Science, Health, Research, Drugs, Clinical medicine, Health, Biguanides, Guanidines, Metformin, Anti-diabetic drugs, Diabetes, Type 2 diabetes, Insulin, Dapagliflozin, Pioglitazone/metformin

Anji Pharma (Anji) has initiated a pivotal trial of ANJ900 (delayed-release metformin) in patients with Type 2 diabetes (T2D), including those with varying stages of renal disease.

Key Points: 
  • Anji Pharma (Anji) has initiated a pivotal trial of ANJ900 (delayed-release metformin) in patients with Type 2 diabetes (T2D), including those with varying stages of renal disease.
  • Without metformin, T2D patients with advanced CKD often require high doses of insulin to achieve glucose control, which can increase the risk of severe hypoglycemia.
  • Based on recent evidence that metformins glucose-lowering effects are largely attributed to direct action at the gut wall, Anji is developing a gut-targeted metformin for use in T2D patients with kidney disease.
  • Anji Pharma is a clinical-stage company dedicated to bringing life-changing therapies to patients as efficiently as possible.

Information Update - Certain Metformin diabetes drugs recalled due to the presence or possible presence of NDMA

Retrieved on: 
Wednesday, March 11, 2020
Drugs, RTT, Biguanides, Guanidines, Metformin, Combination drugs, Diabetes, Diabetes management, Pioglitazone/metformin, Biguanide

What to do:You should not stop taking your metformin drug without first discussing options with your health care provider.

Key Points: 
  • What to do:You should not stop taking your metformin drug without first discussing options with your health care provider.
  • Please refer to the Affected products table below for detailed information on the recalled lots.
  • The risks from not having adequate diabetes treatment outweigh any possible effects of exposure to the levels of NDMA found in the recalled products.
  • The following is a list of metformin drugs being recalled in Canada at this time:

Anji Pharmaceuticals Acquires Late-Stage Clinical Asset and Readies for Ph3 Trials in Type 2 Diabetes with Chronic Kidney Disease

Retrieved on: 
Wednesday, May 29, 2019
Health, Biotechnology, Clinical trials, Genetics, Pharmaceutical, Drugs, RTT, Medicine, Biguanides, Clinical medicine, Guanidines, Metformin, Metabolic disorders, Anji, Lactic acidosis, Diabetes, Pioglitazone/metformin

Anji Pharmaceuticals, Inc. (Anji or the Company) today announced the acquisition of global development rights for a novel delayed-release formulation of metformin (Metformin DR).

Key Points: 
  • Anji Pharmaceuticals, Inc. (Anji or the Company) today announced the acquisition of global development rights for a novel delayed-release formulation of metformin (Metformin DR).
  • Having received input from the FDA on its clinical development plan, Anji plans to initiate a pivotal Phase 3 study in patients with Chronic Kidney Disease (Stage 3b/4) later this year.
  • We are extremely excited to add Metformin DR to our late-stage clinical pipeline, noted Dr. Dan Meyers, Chief Medical Officer of Anji.
  • We recognize the importance of new treatment options for patients with type 2 diabetes with advanced kidney disease who cannot take metformin due to risk of lactic acidosis.

First Sub-Analyses from the DECLARE-TIMI 58 Trial Further Support the Cardiovascular Effects of FARXIGA in Type 2 Diabetes

Retrieved on: 
Monday, March 18, 2019
Health, Biotechnology, Clinical trials, Pharmaceutical, Research, Diabetes, Science, Diabetes, Organ systems, Endocrine system, Endocrinology, Dapagliflozin, SGLT2 inhibitor, Diabetes management, Diabetes mellitus, Pioglitazone/metformin, Outline of diabetes

FARXIGA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Key Points: 
  • FARXIGA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
  • FARXIGA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
  • Monitor for hypotension
    Ketoacidosis has been reported in patients with type 1 and type 2 diabetes receiving FARXIGA.
  • Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes and prior myocardial infarction - a sub-analysis from DECLARE TIMI-58 trial.